PURPOSE: Exercise during breast cancer chemotherapy is beneficial but it needs to be maintained into survivorship to optimize long-term benefits. Here, we report the predictors of follow-up exercise behavior 6 months after a randomized exercise trial in breast cancer patients. METHODS:Breast cancer patients (N = 242) initiatingadjuvant chemotherapy were randomly assigned to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their chemotherapy. At baseline and postintervention, data were collected on demographic, medical, behavioral, fitness, psychosocial, and motivational variables. At 6-month follow-up, participants were mailed a questionnaire that assessed exercise behavior over the past 6 months and were categorized as either meeting both aerobic and resistance exercise guidelines, either exercise guideline, or neither exercise guideline. RESULTS:Two hundred one (83.1%) participants provided 6-month follow-up data with 85 (42.3%) meeting neither exercise guideline, 74 (36.8%) meeting either exercise guideline, and 42 (20.9%) meeting both exercise guidelines. In multivariate regression analysis, seven variables independently predicted the likelihood of meeting exercise guidelines at follow-up including higher pretrial exercise (beta = 0.23; P = 0.002), younger age (beta = -0.15; P = 0.028), breast conserving surgery (beta = 0.15; P = 0.033), strength improvements (beta = 0.15; P = 0.028), lower postintervention fatigue (beta = 0.13; P = 0.067), a more positive attitude (beta = 0.12; P = 0.086), and lower postintervention body mass index (beta = -0.11; P = 0.105). CONCLUSION: Exercise behavior 6 months after a randomized trial was predicted by a wide range of demographic, medical, behavioral, fitness, psychosocial, and motivational variables. These findings may help facilitate the uptake of exercise behavior during the transition from breast cancer patient to survivor.
RCT Entities:
PURPOSE: Exercise during breast cancer chemotherapy is beneficial but it needs to be maintained into survivorship to optimize long-term benefits. Here, we report the predictors of follow-up exercise behavior 6 months after a randomized exercise trial in breast cancerpatients. METHODS:Breast cancerpatients (N = 242) initiating adjuvant chemotherapy were randomly assigned to usual care (n = 82), supervised resistance exercise (n = 82), or supervised aerobic exercise (n = 78) for the duration of their chemotherapy. At baseline and postintervention, data were collected on demographic, medical, behavioral, fitness, psychosocial, and motivational variables. At 6-month follow-up, participants were mailed a questionnaire that assessed exercise behavior over the past 6 months and were categorized as either meeting both aerobic and resistance exercise guidelines, either exercise guideline, or neither exercise guideline. RESULTS: Two hundred one (83.1%) participants provided 6-month follow-up data with 85 (42.3%) meeting neither exercise guideline, 74 (36.8%) meeting either exercise guideline, and 42 (20.9%) meeting both exercise guidelines. In multivariate regression analysis, seven variables independently predicted the likelihood of meeting exercise guidelines at follow-up including higher pretrial exercise (beta = 0.23; P = 0.002), younger age (beta = -0.15; P = 0.028), breast conserving surgery (beta = 0.15; P = 0.033), strength improvements (beta = 0.15; P = 0.028), lower postintervention fatigue (beta = 0.13; P = 0.067), a more positive attitude (beta = 0.12; P = 0.086), and lower postintervention body mass index (beta = -0.11; P = 0.105). CONCLUSION: Exercise behavior 6 months after a randomized trial was predicted by a wide range of demographic, medical, behavioral, fitness, psychosocial, and motivational variables. These findings may help facilitate the uptake of exercise behavior during the transition from breast cancerpatient to survivor.
Authors: Sue Kim; Yun Hee Ko; Yoonkyung Song; Min Jae Kang; Hyojin Lee; Sung Hae Kim; Justin Y Jeon; Young Up Cho; Gihong Yi; Jeehee Han Journal: Support Care Cancer Date: 2019-04-10 Impact factor: 3.603
Authors: D Howell; T F Hack; T K Oliver; T Chulak; S Mayo; M Aubin; M Chasen; C C Earle; A J Friedman; E Green; G W Jones; J M Jones; M Parkinson; N Payeur; C M Sabiston; S Sinclair Journal: Curr Oncol Date: 2011-12 Impact factor: 3.677
Authors: Lawson Eng; Dan Pringle; Jie Su; XiaoWei Shen; Mary Mahler; Chongya Niu; Rebecca Charow; Kyoko Tiessen; Christine Lam; Oleksandr Halytskyy; Hiten Naik; Henrique Hon; Margaret Irwin; Vivien Pat; Christina Gonos; Catherine Chan; Jodie Villeneuve; Luke Harland; Ravi M Shani; M Catherine Brown; Peter Selby; Doris Howell; Wei Xu; Geoffrey Liu; Shabbir M H Alibhai; Jennifer M Jones Journal: Support Care Cancer Date: 2018-05-29 Impact factor: 3.603
Authors: Daniel Santa Mina; Crissa L Guglietti; Shabbir M H Alibhai; Andrew G Matthew; Robin Kalnin; Nora Ahmad; Uri Lindner; John Trachtenberg Journal: J Cancer Surviv Date: 2013-12-07 Impact factor: 4.442
Authors: Catherine M Jankowski; Marcia G Ory; Daniela B Friedman; Andrea Dwyer; Sarah A Birken; Betsy Risendal Journal: J Cancer Surviv Date: 2014-08-08 Impact factor: 4.442
Authors: Cheryl L Cox; Michele Montgomery; Kevin C Oeffinger; Wendy Leisenring; Lonnie Zeltzer; John A Whitton; Ann C Mertens; Melissa M Hudson; Leslie L Robison Journal: Cancer Date: 2009-02-01 Impact factor: 6.860